Mode
Text Size
Log in / Sign up

NAC study protocol for early-onset preeclampsia in Lagos hospitals planned for 2026 to 2028

Share
NAC study protocol for early-onset preeclampsia in Lagos hospitals planned for 2026 to 2028
Photo by National Cancer Institute / Unsplash

This project is a planned research study, not a completed trial. It is designed to test whether taking a daily oral tablet containing 600 mg of N-acetylcysteine affects how quickly early-onset preeclampsia becomes severe. The main goal is to measure the time it takes for the condition to progress in pregnant women who are sexually active and aged 18 years or older.

The study would take place in maternity units at two teaching hospitals in Lagos, Nigeria. It is intended for women diagnosed with early-onset preeclampsia between 24 and 34 weeks of pregnancy. Participants would receive either the N-acetylcysteine tablet or a placebo tablet until 34 weeks gestation or delivery, whichever happens first.

No results, safety data, or findings are available yet because the study has not been conducted. Since this is a proof-of-concept protocol, it does not provide evidence that the medication works or is safe. Readers should wait for the trial to finish and for results to be published before considering any changes to their care.

What this means for you:
This is a planned study protocol with no results available yet; do not use for treatment decisions.
Share
More on early-onset preeclampsia